Quality of Life and Illness Acceptance among End-Stage Renal Disease (ESRD) Patients on Hemodialysis: The Moderating Effect of Death Anxiety during COVID-19 pandemic OMEGA—Journal of Death and Dying 2022, Vol. 0(0) 1–20 © The Author(s) 2022 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/00302228221075202 journals.sagepub.com/home/ome SAGE

Iqra Mushtaque¹, Muhammad Awais-E-Yazdan², Rabab Zahra³, and Muhammad Anas³

Abstract

The purpose of the study was to examine the quality of life and illness acceptance among ESRD patients with the moderating effects of death anxiety. The cross-sectional design was incorporated. The sample was comprised of 240 participants. Individuals with ESRD on hemodialysis were approached above 20 years of age. A selfadministered questionnaire was used for data collection. The results revealed that COVID-19 has a significant impact on the quality of life of patients and their illness acceptance. Covid-19 affected the general health of patients, their psychological health, as well as their social relationships. The results also confirmed that death anxiety negatively moderates the relationship between quality of life and illness acceptance among ESRD patients. This study will shed light on the need to provide appropriate

²College of Business, Universiti Utara Malaysia, Malaysia (UUM), Malaysia

³Govt Said Mitha Teaching Hospital Lahore, Lahore, Pakistan

Corresponding Author:

Muhammad Awais-E-Yazdan, College of Business, Universiti Utara Malaysia, Malaysia (UUM), Sintok, Kedah Darul Aman, 06010, Malaysia. Email: awais.yazdan@gmail.com

¹BZU, Bahadur Sub Campus Layyah, Multan, Pakistan

psychosocial care as well as supportive therapies to people with end-stage renal disease who are experiencing mental distress during and after the COVID-19 outbreak.

Keywords

end-stage renal disease, Covid-19, death anxiety, quality of life, psychological distress

Introduction

In late 2019, a new acute respiratory disease named Corona virus, commonly known as COVID-19, spread around the globe and became an outbreak. That is why it was declared a pandemic by the World Health Organization (World Health Organization, 2019). COVID-19 pandemic situations always have a negative impact on the mental health and well-being of people (Pfefferbaum & North, 2020). The COVID-19 pandemic has badly affected education (Mushtaque, Rizwan, 2021), health, labor, and even every segment of life. Hospitals are places that are at high risk of COVID-19 virus circulation because they are places that all of us visit and where every sick person can easily approach. Some people who are suffering from chronic diseases need to visit the hospital for their care. Health professionals are at high risk of disease contamination and are part of the COVID-19 epidemic. The World Health Organization has recommended reducing elective health operations (dental, skin, ENT) (Moraes et al., 2020). COVID-19 affected the public health system adversely, and all the elective departments of the health system reduced their activities to avoid disease spread and contamination of health staff (Mushtaque, Rizwan, 2021) and the general public (Chisini et al., 2020).

End-Stage Renal Disease (ESRD) or Chronic Renal Failure is a stage of chronic kidney disease (CKD) that occurs when the kidneys lose function and the disease progresses to an advanced stage, at which point dialysis or a renal transplant is required to stay alive ("Chapter 1: Definition and classification of CKD," 2013). ESRD was recently included in the group of lifestyle diseases of the 21st century. It is a progressive and often irreversible disease. According to studies, ESRD affects approximately 600 million people worldwide, accounting for 6-15% of the global population. The number of peritoneal and hemodialysis patients is expected to increase to 5.5 million by 2030 (Eckardt et al., 2009). Studies based on health screening camps and communities in Pakistan show that the prevalence of CKD in Pakistan is 16.6%–25%. (Saleem et al., 2015). A study on the Pakistan Renal Data System (PKRDS) in 2020 revealed that in Pakistan there are a total of 31 hemodialysis units and 658 machines, 440 of which are for hepatitis-ve, 190 for hepatitis C-ve, and 27 machines for hepatitis B-ve. In this study, samples were collected from a total of 990 patients. They also analyzed the causes of ESRD and concluded that out of 990 total patients, 327 were suffering from diabetic nephropathy, 317 with hypertension, 71 with glomerulonephritis, 31 with stones, 2 from polycystic kidney disease, and 105 from other causes. The hepatitis anti-HCV-ve patients, while 22 were unknown and 302 were HCV PCR +ve. The Hepatitis B status indicates that there were 14 HBsAg +ve and 877 were HBsAg-ve, while the 99 others were unknown. In Pakistan, they explored the gender disparity of 35% of females and 65% of males suffering from ESRD (Ahmad & Javed, 2021).

Illness acceptance plays a vital role in chronic disease treatment, which is necessary for the better quality of life of patients. Therefore, psychosocial support is critical, as patients with ESRD face many restrictions, such as dietary, physical, and social, while on dialysis. As a result, psychological and social care are important for the acceptance of illness and quality of life (Jankowska-Polaska et al., 2016). A higher level of disease acceptance was shown among transplant patients than among dialysis patients, which is related to their demographic characteristics. As the patient recognizes the disease, they are more likely to exhibit appropriate disease-related behavior (Chan, 2012). End-Stage Renal Disease development and progression is a significant cause of premature mortality and reduced quality of life (Benjamin & Lappin, 2021). Acceptance of illness leads to a higher quality of life for patients suffering from chronic disease (Zahra et al., 2020). A low level of quality of life in ESRD patients is associated with disease complications and psychological issues (Dbrowska-Bender et al., 2018).

ESRD is critical and fatalities are associated with comorbidities such as cardiovascular diseases, hypertension, diabetes mellitus, and psychological disorders. ESRD is a serious and progressive disease that needs long-term treatment and, as its name indicates, is end-stage renal disease, so it has a negative effect on the people who are suffering from it. People who have a chronic disease are more likely to be diagnosed with psychological problems, as are people with chronic kidney disease, who are prone to being diagnosed with psychological disorders (Goh & Griva 2018).

Another concomitant concern among ESRD patients is anxiety. Many studies have shown that ESRD patients have a significant level of anxiety. According to a previous study, the prevalence of anxiety related to ESRD was estimated at around 13%–52% (Pretto et al., 2020). Another study identified a positive, significant correlation between depression and anxiety with the performance status of ESRD patients (Rajan, E. J. E., & Subramanian, S. (2016). Patients with ESRD face physical, psychological, and spiritual complications as well as lower quality of life that decrease their survival rates and increase thoughts about death, which cause death anxiety (Cohen et al., 2016).

The coronavirus disease 2019 (COVID-19) has the potential to impair hemodialysis patients with ESRD's mental and social well-being. In a study, more than 85% of participants were apprehensive about receiving dialysis treatments due to the risk of infection from close contact at the dialysis facility or during transportation. Thirty percent of people have reported extreme stress and thoughts of death, and 85% report feeling overwhelmed by COVID-19 problems (Gansevoort & Hilbrands, 2020; Lee et al., 2020).Kidney involvement, as demonstrated by hematuria and proteinuria, was found to be an independent predictor of in-hospital death (Docherty et al., 2020). The higher frequency of acute kidney injury and mortality due to renal-related

complications documented in observational studies could be explained in part by SARS-CoV-2 kidney tropism and systemic immune responses to the virus (Cheng et al., 2020).

In order to fill the gap, as death anxiety has taken a terrible toll on our society globally for a variety of reasons, during the pandemic the prevalence of death anxiety among chronically ill patients is very new and not well documented at all. The purpose of the present research was to examine the quality of life and illness acceptance among end-stage renal disease patients on hemodialysis and the moderating role of death anxiety during lockdown.

Hypothesis of the Study

H1. There is likely to be a significant association between quality of life, illness acceptance among end-stage renal disease patients

H2. There is likely to be death anxiety negatively moderates the relationship between quality of life, illness acceptance among end-stage renal disease patients

Material and Method of the Study

Sample, Data Collection, and Design

The data was gathered using the purposive sampling technique and self-administered questionnaires. G Power was used to calculate the sample size (Services Hospital, Mayo Hospital, General Hospital Dialysis Center, and Govt. Said Mitha Teaching Hospital in Lahore, Pakistan). The current study's sample was collected from the anonymized kidney and dialysis unit. The study included 240 people, ranging in age from 20 to 85. The following criteria apply to the cross-sectional study: Patients with end-stage renal illness who underwent dialysis on a regular basis at the hospital during COVID-19 and who had received at least 2 years of hemodialysis treatment had no significant comorbidities (e.g., cancer) and a diagnosis of depression with cognitive dysfunction.

Instruments

The instruments include a socio-demographic form for each participant. All the scales used in the current study were in Urdu, the national language of Pakistan. So that the respondent can easily understand the statements and provide a reliable response.

Felton & Revenson (1984) developed the Illness Acceptance Scale. This scale allows the researcher to assess the patient's level of acceptance of any illness. It consists of eight assertions about the negative aspects of inadequate well-being. It's a 5-point Likert scale, with responses ranging from 1 to 5, with 1 being weak and 5 being extremely strong. Zahra et al. translated the Urdu-adapted version of the Illness acceptance scale (2019) that was used in the current study. Cronbach's alpha value of the

illness acceptance scale is 0.950. The score range of the illness acceptance scale is (8–40), whereas, value (8–18) considered as lack of illness acceptance, value (19–29) considered as moderate, and value (30–40) considered as high level of illness acceptance.

Quality of Life (WHOQOL-BREF) questionnaire—Urdu, translated by Saqib Lodhi et al. (2017). It is a 26-item scale. The Urdu version of the World Health Organization's quality of life questionnaire (WHOQOL-BREF) scale has excellent psychometric characteristics. As a result, it can be used to assess the quality of life among Pakistanis as a valid technique. In the current study, the Cronbach's alpha value of the quality of life scale is 0.921.

The Death Anxiety Scale-Urdu (DAS-U) is reliable and valid. The Death Anxiety Questionnaire is a 15-item self-report measure used with a population recruited against a life-threatening illness. The score range of the scale is (15-75), whereas value (15-35) considered as low death anxiety, value (36-55) considered as moderate, and value (56-75) considered as high level of death anxiety. It is a five-point Likert scale. The Cronbach's alpha value of the death anxiety scale is 0.970. (Saleem et al., 2015).

Procedure

In this study, we looked at the data from 240 patients with end-stage renal illness. For this purpose, we approached the four different hospital dialysis wards anonymized. Participants first read the study's purpose and gave informed consent before moving on to the next page, which contained the questionnaire. The demographics, illness acceptance scale, quality of life, and death anxiety scale are all included in the questionnaire. All instruments were reviewed for the accuracy of the researcher's written information before data entry and coding. All the data was entered into a spreadsheet for statistical reasons after following the instructions and data coding. To avoid data input errors and other potential blunders, all data was imported into SPSS. 50 people were ruled out due to missing information and inadequate response.

Ethical Approval

The ethical approval was taken from the research and ethical review committee of anonymized.

Statistical Analysis

The demographic data was subjected to descriptive analysis, whereas the study variables were examined using PLS-SEM.

Demographic Variables	f(%)
Gender	
Male	141(58.8)
Female	99(41.3)
Age of the participant	
25–35	44(18.3)
3645	63(26.3)
46–55	45(18.8)
56–65	74(30.8)
66–75	14(5.8)
Qualification of the participant	
Vocational education	42(17.5)
High school	131(54.6)
College/University	10(4.2)
Uneducated	57(23.8)
Socioeconomic status	, , , , , , , , , , , , , , , , , , ,
Upper	3(1.3)
Middle	67(27.9)
Lower	170(70.8)
Any other disease with ESDR	, , , , , , , , , , , , , , , , , , ,
Diabetes	80(33.3)
Hepatitis	70(29.2)
High blood pressure	47(19.6)
No disease	43(17.9)
Any other mental illness with ESDR	, , , , , , , , , , , , , , , , , , ,
Yes	10(4.1)
No	230(95.8)
Insomnia	193(80.4)
Muscle cramp	190(80.0)
Fatigue	232(97.3)
Hospitalization during the period of COVID-19	122(50.8)

Table 1. Demographic characteristics of the ESDR Patients included in the study (240).

Result of the Study

The (Table 1) depicts the demographic features of the study participants, who were 58% male and 41% female. The majority of participants are between the ages of 56 and 65 and come from the middle and lower classes. The data were collected during the COVID-19 period, when patients were required to attend during a critical period since they did not receive treatment at home. Which revealed that 50% of respondents had been hospitalized during the duration of COVID-19. Patients with ESDR reported comorbidities such as hepatitis, hypertension, and diabetes; only 17% of patients



Figure 1. Conceptual frame-work of the study.

reported no comorbidity with ESDR, and 4% reported psychological comorbidity with ESDR.

Assessment of Measurement Model

The present study incorporated structural equation modeling (SEM) technique using Smart PLS 3.2.6 to examine the measurement model. There are two steps of measurement model: convergent validity and discriminant validity. Measurement model with its features were exhibited in the Figure 2.

The present study examined convergent validity with three steps, namely; individual item reliability, internal consistency reliability, and average variance extracted (AVE) (Table 2). The factor loading of every construct is known as individual item reliability (Hair et al., 2016.; Hulland, 1999). Each item of a construct has a different and unique factor loading. The loading of a construct above 0.30 can be retained in the model as the minimum acceptable loading value of a construct is 0.30 (Hair et al. 2016). Hair et al. (2016) stated that items of the construct must be removed if the removal helps in increasing the value of AVE and composite reliability (CR). Hence, the current study did not report any removal of items as the removal of items failed to increase the value of AVE and CR. In addition, the second step for the assessment of convergent validity is internal consistency reliability. The internal consistency reliability can be examined by the CR of the construct. According to previous studies, Cronbach's alpha and CR are appropriate for the successful examination of internal consistency reliability (Hair et al., 2014). The value of CR must be above than 0.70 (Hair et al., 2017). By following the recommendations of Hair et al. (2017), each item of the present study exhibited the value above than 0.70. In the third step, the study determined AVE to examine convergent validity. In order to evaluate the perfect convergent validity, the value of AVE must be greater than 0.50 (Fernandes, 2012; Hair et al., 2014). The convergent



Figure 2. Measurement model

validity of the present study is accurate as every construct represented the value of AVE above than 0.50.

The second step in measurement model is the assessment of discriminant validity. Discriminant validity determines the degree of variance among the constructs (Hair et al., 2010). Discriminant validity is examined through Fornell-Larcker's (1981) criteria, cross-loadings, and heterotrait-monotrait ratio (HTMT). Firstly, in Fornell-Larcker's (1981), the first value of every construct must be bold. The diagonal value of discriminant validity shows the square root of AVE. The discriminant validity is considered valid if the diagonal values are greater than non-diagonal values in respected rows and columns. Table 3 denotes the acceptance values of discriminant validity and illustrates that all values are in acceptable range. Secondly, crossloadings are another criteria for the assessment of discriminant validity (Grégoire & Fisher, 2006). The cross-loadings of each construct must be greater than the crossloadings with other constructs. Table 4 exhibits the acceptable cross-loadings of the constructs. Thirdly, heterotrait-monotrait ratio (HTMT) is another criteria to measure discriminant validity (Henseler et al., 2015). HTMT is a factor correlation which differentiate among constructs (Henseler et al., 2016). Table 5 represents the HTMT value of the constructs.

Death anxiety DA1 0.812 0.709 0.973 DA2 0.874 DA3 0.909 DA4 0.894 DA5 0.861 DA5 0.861 DA6 0.823 DA7 0.850 DA8 0.811 DA9 0.840 DA10 0.830 DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.736 0.957 ENVironment EN1 0.759 0.736 0.957 EN2 0.864 EN3 0.876 EN4 0.858 EN5 0.827 EN4 0.856 EN7 0.914 EN8 0.902 General health GH1 0.914 O.865 0.928 Illness acceptance IA1 0.820 0.794 0.969 IA3 0.927 IA4 0.904 IA3 0.927 IA4 0.905 IA7 0.905 IA7 0.905 IA7 0.905 IA7 0.905	Constructs	Items	Loadings	AVE	CR
DA2 0.874 DA3 0.909 DA4 0.894 DA5 0.861 DA6 0.823 DA7 0.850 DA8 0.811 DA9 0.840 DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 DA15 0.766 Environment EN1 0.759 0.736 0.957 Environment EN1 0.759 0.736 0.957 Environment EN1 0.759 0.736 0.957 General health GH1 0.914 0.865 0.928 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 IA5 0.853 IA6 0.901 IA3 0.901 0.739 0.952 IA6 0.901 IA7 0.905 IA4 0.904 IA5 0.853 <td< td=""><td>Death anxiety</td><td>DAI</td><td>0.812</td><td>0.709</td><td>0.973</td></td<>	Death anxiety	DAI	0.812	0.709	0.973
DA3 0.909 DA4 0.894 DA5 0.861 DA6 0.823 DA7 0.850 DA8 0.811 DA9 0.840 DA10 0.830 DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 Environment EN1 EN1 0.759 0.736 EN2 0.864 EN3 0.876 EN4 0.827 EN6 0.826 EN7 0.914 EN8 0.902 General health GH2 0.904 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 IA5 0.853 IA6 0.905 IA7 0.909 IA3 0.901 IA8 0.901 IA6 0.908 IA6 0.908 <	-	DA2	0.874		
DA4 0.894 DA5 0.861 DA6 0.823 DA7 0.850 DA8 0.811 DA9 0.840 DA10 0.830 DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 Environment EN1 0.759 EN2 0.864 EN3 0.876 EN4 0.858 EN5 0.827 EN6 0.856 EN7 0.914 General health GH1 0.914 Illness acceptance IA1 0.820 0.736 IA3 0.927 IA4 0.904 IA5 0.853 IA66 0.905 IA7 0.904 IA5 0.853 IA6 0.905 IA7 0.905 IA7 0.908 IA66 0.905 IA7 0.908		DA3	0.909		
DA5 0.86 DA6 0.823 DA7 0.850 DA8 0.811 DA9 0.840 DA10 0.830 DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 Environment EN1 0.759 0.736 0.957 EN2 0.864 1		DA4	0.894		
DA6 0.823 DA7 0.850 DA8 0.811 DA9 0.840 DA10 0.830 DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 DA15 0.766 Environment ENI 0.759 EN1 0.759 0.736 0.957 EN4 0.856 1 EN4 0.856 1 1 EN5 0.827 1 1 General health GH1 0.914 0.865 0.928 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 1 1 1 1 Physical health GH2 0.904 1 1 0.905 IA6 0.905 1 1 0.905 1 1 0.905 IA7 0.909 1 0.739 <td></td> <td>DA5</td> <td>0.861</td> <td></td> <td></td>		DA5	0.861		
DA7 0.850 DA8 0.811 DA9 0.840 DA10 0.830 DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 Environment EN1 0.759 0.736 0.957 EN2 0.864 0.802 0.736 0.957 EN2 0.864 0.806 0.957 0.736 0.957 EN3 0.876 0.817 0.914 0.865 0.928 General health GH1 0.914 0.865 0.928 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 IA3 0.927 IA4 0.904 IA5 0.853 IA7 0.909 IA7 0.909 IA6 0.901 IA7 0.909 IA7 0.905 IA7 0.908 IA7 0.908 IA7 0.908		DA6	0.823		
DA8 0.81 I DA9 0.840 DA10 0.830 DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 Environment EN1 0.759 0.736 0.957 Environment EN1 0.864 0.864 EN2 0.864 0.858 0.827 EN4 0.858 0.827 0.736 0.928 General health GH1 0.914 0.865 0.928 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 1.43 0.927 1.44 0.904 IA3 0.927 1.44 0.904 1.45 0.853 IA6 0.905 1.47 0.909 1.44 0.904 IA5 0.853 1.47 0.909 1.44 0.901 Physical health PH1 0.799 0.739 0.952		DA7	0.850		
DA9 0.840 DA10 0.830 DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 DA15 0.766 Environment ENI 0.759 0.736 0.957 EN2 0.864 0.836 0.836 0.836 EN3 0.876 0.856 0.827 0.864 0.901 0.865 0.928 General health GH1 0.914 0.865 0.928 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 1.43 0.902 0.736 0.951 IA3 0.927 I.44 0.904 1.43 0.904 IA5 0.853 I.46 0.905 I.47 0.909 IA6 0.905 I.47 0.908 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830		DA8	0.811		
DA10 0.830 DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 Environment EN2 0.864 EN3 0.876 EN4 0.858 EN5 0.827 EN6 0.8366 EN7 0.914 EN8 0.902 General health GH1 0.914 GH2 0.946 Illness acceptance IA1 0.820 0.794 IA3 0.927 IA4 0.904 IA5 0.853 IA6 0.905 IA6 0.905 IA7 0.909 IA6 0.905 IA7 0.908 Physical health PH1 0.799 0.739 0.952 PH3 0.908 PH4 0.851 PH5 0.830 PH5 0.830		DA9	0.840		
DA11 0.866 DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 DA13 0.842 DA14 0.759 DA15 0.766 EN1 0.759 0.736 0.957 EN2 0.8644 0.858 0.876 EN4 0.858 0.827 0.736 0.928 EN5 0.827 0.914 0.865 0.928 General health GH1 0.914 0.865 0.928 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 IA3 0.927 IA4 0.904 IA5 0.853 IA6 0.905 IA7 0.909 IA6 0.901 0.739 0.952 Physical health PH1 0.799 0.739 0.952 PH3 0.908 PH4 0.801 PH5 0.830 PH5 0.830 </td <td></td> <td>DA10</td> <td>0.830</td> <td></td> <td></td>		DA10	0.830		
DA12 0.851 DA13 0.842 DA14 0.793 DA15 0.766 DA15 0.766 Environment EN1 0.759 0.736 0.957 EN2 0.864 0.876 0.876 0.957 EN3 0.876 0.876 0.957 0.736 0.957 EN4 0.858 0.827 0.876 0.914 0.858 0.902 0.914 0.858 0.928 0.914 0.914 0.865 0.928 0.914		DAII	0.866		
DA13 0.842 DA14 0.793 DA15 0.766 Environment EN1 0.759 0.736 0.957 EN2 0.864 0.876 0.957 0.957 EN2 0.864 0.856 0.957 0.914 0.914 0.902 0.914 EN8 0.902 0.914 0.914 0.865 0.928 General health GH1 0.914 0.865 0.928 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 1A3 0.927 1A4 0.904 IA5 0.853 1A6 0.905 1A7 0.909 IA6 0.905 1A7 0.909 1A8 0.901 1A9 0.952 Physical health PH1 0.799 0.739 0.952 PH3 0.808 1944 0.851 144 0.908 PH4 0.851 1945 0.830 144 145 <		DA12	0.851		
DA14 0.793 DA15 0.766 ENI 0.759 0.736 0.957 EN2 0.864 EN3 0.876 EN4 0.858 EN5 0.827 EN6 0.856 EN7 0.914 EN8 0.902 General health GH1 0.914 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 1A3 0.927 1A4 0.904 Physical health PH1 0.739 0.739 0.952 Physical health PH1 0.799 0.739 0.952 PH4 0.851 146 0.901 145		DA13	0.842		
DA I 5 0.766 Environment EN I 0.759 0.736 0.957 EN2 0.864 0.876 0.876 0.876 EN3 0.876 0.858 0.827 0.864 0.856 EN5 0.827 0.914 0.865 0.928 General health GH1 0.914 0.865 0.928 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 0.794 0.969 IA3 0.927 1.44 0.904 IA5 0.853 1.46 0.901 IA5 0.853 1.47 0.909 IA8 0.901 1.48 0.901 Physical health PH1 0.799 0.739 0.952 PH2 0.854 1.43 0.908 PH4 0.851 1.46 0.805 PH4 0.851 1.45 0.830 PH4 0.830 1.46 0.895		DAI4	0.793		
Environment ENI 0.759 0.736 0.957 EN2 0.864 1 <t< td=""><td></td><td>DA15</td><td>0.766</td><td></td><td></td></t<>		DA15	0.766		
EN2 0.864 EN3 0.876 EN4 0.858 EN5 0.827 EN6 0.856 EN7 0.914 EN8 0.902 General health GH1 0.914 EN8 0.902 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 0.433 0.927 144 0.904 IA5 0.853 1A6 0.905 1A7 0.909 IA8 0.901 1A8 0.901 148 0.905 Physical health PH1 0.799 0.739 0.952 PH2 0.854 149 0.908 PH4 0.851 146 145 PH3 0.908 144 0.851 PH3 0.908 144 0.851 PH5 0.830 146 145	Environment	ENI	0.759	0.736	0.957
EN3 0.876 EN4 0.858 EN5 0.827 EN6 0.856 EN7 0.914 EN8 0.902 General health GH1 0.914 GH2 0.946 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 1A3 0.927 1A4 0.904 IA5 0.853 1A6 0.905 1A7 0.909 IA8 0.901 0.739 0.952 Physical health PH1 0.799 0.739 0.952 PH2 0.854 143 0.908 PH4 0.851 144 0.808 PH2 0.854 143 145 145 PH3 0.908 144 145 145 145 PH2 0.854 145 145 145 145 145 PH3 0.908 144 0.851 145 145 145<		EN2	0.864		
EN4 0.858 EN5 0.827 EN6 0.856 EN7 0.914 EN8 0.902 General health GH1 0.914 GH2 0.946 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 1A3 0.927 1A4 0.904 IA5 0.853 1A6 0.905 1A7 0.909 IA8 0.901 1A8 0.901 945 Physical health PH1 0.799 0.739 0.952 PH2 0.854 143 0.908 144 0.851 PH3 0.908 144 0.851 145 <td rowspan="2"></td> <td>EN3</td> <td>0.876</td> <td></td> <td></td>		EN3	0.876		
EN5 0.827 EN6 0.856 EN7 0.914 EN8 0.902 General health GH1 0.914 GH2 0.946 Illness acceptance IA1 0.820 IA2 0.904 IA3 0.927 IA4 0.904 IA5 0.853 IA6 0.905 IA7 0.909 IA8 0.901 Physical health PH1 0.799 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830		EN4	0.858		
EN6 0.856 EN7 0.914 EN8 0.902 General health GH1 0.914 GH2 0.946 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 1A3 0.927 1A4 0.904 IA5 0.853 1A6 0.905 1A7 0.909 IA8 0.901 1A8 0.901 0.739 0.952 Physical health PH1 0.799 0.739 0.952 PH2 0.854 144 0.908 145 145 PH2 0.854 144 0.908 145 145 PH2 0.854 145<		EN5	0.827		
EN7 0.914 EN8 0.902 General health GH1 0.914 0.865 0.928 GH2 0.946 0.794 0.969 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 1A3 0.927 1A4 0.904 IA5 0.853 1A6 0.905 1A7 0.909 IA8 0.901 1A8 0.901 0.952 Physical health PH1 0.799 0.739 0.952 PH2 0.854 144 0.908 144 145 145 PH3 0.908 145		EN6	0.856		
EN8 0.902 General health GH1 0.914 0.865 0.928 GH2 0.946 0.794 0.969 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 1A3 0.927 IA4 0.904 1A5 0.853 IA6 0.905 1A7 0.909 IA8 0.901 1A8 0.915 Physical health PH1 0.799 0.739 0.952 PH2 0.854 144 0.908 144 0.908 PH4 0.851 144 0.908 145		EN7	0.914		
General health GH1 0.914 0.865 0.928 GH2 0.946 0.946 0.969 0.969 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 0.904 0.904 0.904 IA3 0.927 1A4 0.904 0.905 IA5 0.853 1A6 0.905 IA7 0.909 1A8 0.901 Physical health PH1 0.799 0.739 0.952 PH2 0.854 143 0.908 144 0.908 PH4 0.851 145 0.830 146 0.895		EN8	0.902		
GH2 0.946 Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 IA3 0.927 IA4 0.904 IA5 0.853 IA6 0.905 IA7 0.909 IA8 0.901 PH1 0.799 0.739 0.952 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895 IA80 IA80	General health	GHI	0.914	0.865	0.928
Illness acceptance IA1 0.820 0.794 0.969 IA2 0.904 IA3 0.927 IA4 0.904 IA5 0.853 IA6 0.905 IA7 0.909 IA8 0.901 PH1 0.739 0.952 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895 IA80 0.905		GH2	0.946		
IA2 0.904 IA3 0.927 IA4 0.904 IA5 0.853 IA6 0.905 IA7 0.909 IA8 0.901 Physical health PH1 0.799 0.739 0.952 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895 0.905	Illness acceptance	IAI	0.820	0.794	0.969
IA3 0.927 IA4 0.904 IA5 0.853 IA6 0.905 IA7 0.909 IA8 0.901 Physical health PH1 0.799 0.739 0.952 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895		IA2	0.904		
IA4 0.904 IA5 0.853 IA6 0.905 IA7 0.909 IA8 0.901 Physical health PH1 0.799 0.739 0.952 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895		IA3	0.927		
IA5 0.853 IA6 0.905 IA7 0.909 IA8 0.901 Physical health PH1 0.799 0.739 0.952 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895		IA4	0.904		
IA6 0.905 IA7 0.909 IA8 0.901 Physical health PH1 0.799 0.739 0.952 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895		IA5	0.853		
IA7 0.909 IA8 0.901 Physical health PH1 0.799 0.739 0.952 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895		IA6	0.905		
IA8 0.901 Physical health PH1 0.799 0.739 0.952 PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895 PH6 0.895		IA7	0.909		
Physical health PHI 0.799 0.739 0.952 PH2 0.854 <		IA8	0.901		
PH2 0.854 PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895	Physical health	PHI	0.799	0.739	0.952
PH3 0.908 PH4 0.851 PH5 0.830 PH6 0.895		PH2	0.854		
PH4 0.851 PH5 0.830 PH6 0.895		PH3	0.908		
PH5 0.830 PH6 0.895		PH4	0.851		
PH6 0.895		PH5	0.830		
		PH6	0.895		

Table 2. Loadings, Composite Reliability, and Average Variance Extracted.

(continued)

Constructs	ltems	Loadings	AVE	CR
	PH7	0.872		
Psychological	PSI	0.820	0.719	0.939
, C	PS2	0.893		
	PS3	0.891		
	PS4	0.817		
	PS5	0.813		
	PS6	0.848		
Social relationships	SRI	0.862	0.762	0.906
	SR2	0.884		
	SR3	0.874		

Table 2. (continued)

Note. AVE = average variance extracted, CR = composite reliability.

 Table 3.
 Latent Variable Correlations and Square Roots of Average Variance Extracted (AVE).

	DA	EN	GH	IA	PH	PS	SR
DA	0.842						
EN	0.587	0.858					
GH	0.423	0.537	0.930				
IA	0.778	0.436	0.504	0.891			
PH	0.523	0.530	0.356	0.655	0.859		
PS	0.547	0.517	0.310	0.671	0.745	0.848	
SR	0.492	0.502	0.446	0.532	0.522	0.533	0.873

Note. Entries in the boldface represent the square root of average variance extracted (AVE) DA = DeathAnxiety, IA, Illness Acceptance, EN = Environment, GH = General health, PH = Physical Health, PS = Psychological Health, SR = Social Relationship.

Assessment of Structural Model

The next step of the SEM is the structural model also known as inner model. The relationship among the constructs can be determined by structural model. Bootstrap technique of SEM provides the results for the structural model. The current study determined quality of life as a second order construct. Figure 3 depicts the assessment of the structural model.

The inner model shows the path coefficients of the hypothesized relationships of the study. Hypothesis H1 predicted that there is a significant relationship between quality of life and illness acceptance. The outcomes represented in Figure 3 and Table 6 indicate that there is a significant relationship between quality of life and illness acceptance (β = 0.247; *t* = 5.594; *p* < 0.000). Similarly, hypothesis H2 stated that death anxiety negatively moderates the relationship between quality of life and illness acceptance. The interaction effect in Figure 3 and Table 6 depicts that death anxiety negatively

Table 4. Cross-Loadings	•
---------------------------------	---

	DA	EN	GH	IA	PH	PS	SR
DAI	0.812	0.524	0.454	0.778	0.521	0.532	0.523
DA2	0.874	0.531	0.433	0.818	0.556	0.578	0.531
DA3	0.909	0.547	0.367	0.754	0.518	0.547	0.485
DA4	0.894	0.543	0.290	0.716	0.527	0.566	0.495
DA5	0.861	0.477	0.295	0.575	0.371	0.380	0.389
DA6	0.823	0.495	0.451	0.655	0.450	0.471	0.448
DA7	0.850	0.443	0.345	0.651	0.409	0.424	0.432
DA8	0.811	0.528	0.337	0.591	0.446	0.460	0.415
DA9	0.840	0.445	0.252	0.609	0.402	0.439	0.348
DAI0	0.830	0.505	0.279	0.577	0.404	0.408	0.386
DAII	0.866	0.460	0.326	0.626	0.405	0.430	0.324
DAI2	0.851	0.472	0.403	0.628	0.357	0.381	0.389
DA13	0.842	0.521	0.349	0.617	0.425	0.455	0.386
DAI4	0.793	0.498	0.381	0.594	0.374	0.411	0.267
DA15	0.766	0.390	0.341	0.502	0.346	0.326	0.273
ENI	0.429	0.759	0.454	0.320	0.406	0.384	0.457
EN2	0.490	0.864	0.554	0.390	0.421	0.414	0.557
EN3	0.499	0.876	0.462	0.392	0.502	0.491	0.429
EN4	0.441	0.858	0.391	0.365	0.471	0.456	0.397
EN5	0.519	0.827	0.317	0.294	0.455	0.445	0.296
EN6	0.468	0.856	0.542	0.447	0.455	0.456	0.510
EN7	0.572	0.914	0.485	0.391	0.470	0.459	0.398
EN8	0.605	0.902	0.469	0.381	0.451	0.440	0.396
GHI	0.376	0.433	0.914	0.452	0.263	0.227	0.449
GH2	0.409	0.553	0.946	0.483	0.386	0.338	0.389
IAI	0.586	0.264	0.495	0.820	0.503	0.521	0.366
IA2	0.701	0.381	0.454	0.904	0.565	0.584	0.484
IA3	0.764	0.449	0.518	0.927	0.602	0.608	0.508
IA4	0.686	0.375	0.372	0.904	0.620	0.632	0.427
IA5	0.641	0.393	0.313	0.853	0.626	0.644	0.427
IA6	0.682	0.360	0.495	0.905	0.565	0.582	0.518
IA7	0.748	0.418	0.486	0.909	0.579	0.598	0.549
IA8	0.716	0.442	0.456	0.901	0.602	0.610	0.491
PHI	0.388	0.346	0.285	0.504	0.799	0.747	0.331
PH2	0.441	0.479	0.355	0.565	0.854	0.800	0.375
PH3	0.501	0.453	0.241	0.596	0.908	0.869	0.469
PH4	0.524	0.469	0.166	0.567	0.851	0.812	0.449
PH5	0.519	0.432	0.408	0.658	0.830	0.739	0.527
PH6	0.434	0.456	0.342	0.589	0.895	0.857	0.450

П

(continued)

	,						
	DA	EN	GH	IA	PH	PS	SR
PH7	0.342	0.539	0.341	0.461	0.872	0.803	0.525
PSI	0.441	0.367	0.353	0.553	0.780	0.820	0.371
PS2	0.447	0.465	0.224	0.548	0.857	0.893	0.461
PS3	0.492	0.479	0.207	0.568	0.813	0.891	0.472
PS4	0.485	0.454	0.151	0.530	0.773	0.817	0.399
PS5	0.511	0.439	0.345	0.641	0.756	0.813	0.506
PS6	0.412	0.421	0.303	0.575	0.825	0.848	0.496
SRI	0.454	0.455	0.469	0.539	0.496	0.502	0.862
SR2	0.429	0.399	0.332	0.473	0.462	0.469	0.884
SR3	0.400	0.459	0.359	0.371	0.404	0.421	0.874

Table 4.	(continued)
	· · · · · · · · · · · · · · · · · · ·

Note: DA = Death Anxiety, IA, Illness Acceptance, EN = Environment, GH = General health, PH = Physical Health, PS = Psychological Health, SR = Social Relationship.

	DA	EN	GH	IA	PH	PS	SR
DA							
EN	0.609						
GH	0.461	0.591					
IA	0.791	0.452	0.557				
PH	0.540	0.559	0.391	0.688			
PS	0.571	0.553	0.345	0.713	0.723		
SR	0.531	0.560	0.583	0.583	0.581	0.601	

Table 5. HTMT Correlation Matrix for Discriminant Validity.

Note: DA = Death Anxiety, IA, Illness Acceptance, EN = Environment, GH = General health, PH = Physical Health, PS = Psychological Health, SR = Social Relationship.

moderates the relationship between quality of life and illness acceptance ($\beta = -0.265$; t = 5.955; p < 0.000).

The interaction effect is presented in the Figure 4. Exogenous construct is shown on x-axis and endogenous construct is shown on y-axis. The simple slope plot represents the relationship between independent and dependent variable for high and low level of moderator by three lines (green, red, and blue). Green and blue lines emphasize the low and high level of moderator, whereas the red line denotes the effect of independent variable on dependent variable except moderating effect.

Discussion

Chronic renal failure is treated in patients who require long-term dialysis. Both hemodialysis and peritoneal dialysis have a profound impact on the lives of patients.



Figure 3. Structural Model (Direct relationship and Moderating Effect).

Hypothesis	Relationships	Beta	SE	T-value	p-value	Decision
HI	QOL -> IA	0.247	0.044	5.594	0.000	Supported
H2	QOL *DA-> IA	-0.265	0.044	5.955	0.000	Supported

Table 6. Structural Model Assessment with Interactions.

Note: QOL = quality of life, IA = illness acceptance, DA = death anxiety.

Hemodialysis is a life-sustaining treatment for those with end-stage renal illness. Hemodialysis can have a significant detrimental influence on a person's overall health-related quality of life and outcomes (Zyoud et al., 2016). Many hemodialysis patients report having a poor quality of life in terms of lifestyle, social connections, and mental health (Nataatmadja et al., 2020). Because of their immune-compromised state and frail health, patients undergoing hospital HD are likely to be at a higher risk of getting severe COVID-19 (Gansevoort & Hilbrands, 2020). As a result, the study's aims were to assess ESDR patients' quality of life and illness acceptance during the duration of COVID-19. Because previous research has shown that COVID-19 has a significant impact on patients' psychological health, this study examines the moderating effect of death anxiety.



Figure 4. Interaction Effect of quality of life and death anxiety on illness acceptance.

All Urdu-translated instruments were employed in the current study because Urdu is Pakistan's native language. The findings demonstrated that the instruments employed for data collection were culturally appropriate (Table 2). The scales' convergent validity and reliability vary from 0.70 to 0.90, indicating strong reliability among the indigenous population. In the current study, the majority of the participants were elderly and feeble people over 65 (Table 1). Renal illness patients are a fragile elderly population that has a higher mortality rate than the overall population (Coppolino et al., 2020). The current study's findings demonstrated that the load on self-care rose during the term of the COVID-19. Internalization of disease burden or a lack of acceptance of illness can occur as a result of frequent clinic and hospital visits, food restrictions, increased medication load, and home glucose, blood pressure, and weight monitoring (Song et al., 2017). Patients with ESDR in the current study stated (Table 1) that medical and psychological problems such as diabetes, high blood pressure, hepatitis, anxiety, sleeplessness, heart failure, aches, and fatigues after hemodialysis impacted their quality of life (Dabrowska-Bender et al., 2018). The results revealed that only 4% of respondents had a psychological illness. Thus, the mental health of kidney transplant recipients does not appear to have been adversely affected by the COVID-19 pandemic and seclusion. Patients undergoing hemodialysis were more likely to experience back pain, headaches, and hypertension. Additionally, they indicated a greater onerousness factor related to dialysis (Lee et al., 2020).

The primary goal of this study was to examine quality of life, illness acceptance, and the moderating role of death anxiety in patients with kidney failure receiving hemodialysis in the period of COVID-19. The findings indicated that COVID-19 had an effect on patients' quality of life and acceptance of illness, whereas death anxiety acted as a moderator of the association (Table 6). In this study, quality of life (environment, general health, psychological health, and social relationships) scores were worse. Furthermore, factors linked to social dysfunction tended to be worse. This is unsurprising given that social isolation is a common problem among renal patients (Moorthi & Latham-Mintus, 2019). The significant relationship between poor quality of life and low acceptance of illness shows that anxiety is associated with an increase in a maladaptive attitude toward chronic renal disease (Table 6). Little research has examined the possible relationship between hemodialysis and patient acceptance of chronic renal illness. According to several of these studies, patients with a functioning kidney transplant have a significantly higher acceptance of illness score than patients on hemodialysis (Garca-Llana et al., 2013; Kokoszka et al., 2016). Due to the rigorous and protracted nature of dialysis therapy, as well as the lack of time for work, hobbies, and other social activities, patients on hemodialysis face increased social isolation and support issues (Dbrowska-Bender et al., 2018; Goh & Griva, 2018).

The current study results showed that patients' quality of life, illness acceptance, and suffering from death anxiety have poor quality of life. As a study revealed, acute renal illness has a relatively high mortality rate, even in the absence of COVID-19 infections (Diao et al., 2020). Furthermore, in-patient hospital mortality was 31.7% higher in 133 of 149 COVID-19 positive ESRD patients (Ng et al., 2020). According to another study, 44% of 710 hospitalized patients had proteinuria, 27% had hematuria, and 3.2% had acute renal injury, all of which were associated with a high death rate (Zhang & Parikh, 2019). Patients with chronic renal failure face a conundrum of death anxiety combined with a fear of living. Sixty-four percent of participants in an ESDR trial exhibited high levels of death anxiety. Approximately 70% of the patients had a low or moderate quality of life (Ghiasi et al., 2021). According to the findings, it is vital to address the death anxiety of ESDR patients receiving hemodialysis (Dewina et al., 2018). Healthrelated quality of life is a strong predictor of death and hospitalization, which may influence the prognosis and course of the illness. This decline in quality of life in dialysis patients is a result of death anxiety (Abdul Gafor et al., 2018). Another factor contributing to the current sample's low quality of life may be their old age, low socioeconomic level, and lack of education and unemployment (Table 1). It is crucial to recognize the impact of death anxiety and poor quality of life in patients with end-stage renal disease (ESRD). It also highlights how end stage renal disease patients may be at risk of increased perceptions of death anxiety in the period COVID-19 as well as sleep disorders and psychological distress. Unnecessary delays in addressing these individuals' mental health disorders will have an effect on the result of ESRD management.

Conclusion

COVID-19 poses a major health risk to humans. During the pandemic, the combined action of multiple causes resulted in a slew of psychological issues. Our research discovered some key facts that should be taken into account when treating ESRD patients. The results of the study showed that ESRD patients suffer from death anxiety and poor quality of life that affect their acceptance of illness. Poor quality of life was

connected with elderly patients who had no formal education and lived in a lower socioeconomic stratum. Furthermore, this study found that a lower quality of life was connected with a lower rate of disease acceptance. These findings should be of interest to educators, pharmacists, and clinicians who work with patients suffering from end-stage renal disease (ESRD). To help patients improve their QOL, healthcare professionals should be mindful of patients with inadequate formal education, many physical and psychological co-morbid diseases, and geriatric patients. To summarize, global health measures should be employed to treat psychological stress, especially in patients with end-stage renal disease (ESRD) and other chronic diseases.

Limitation of the Study

Because the study is cross-sectional, a cause-and-effect link between risk factors cannot be established. The target population was only end-stage renal disease. As data was collected in the period of Covid-19 and those patients who visited hospitals and hospitalized for dialysis, during the inquiry and research phases, Pakistan's policy was to shut down Lahore, Punjab, and implement strict prevention and control measures across the country, such as donning masks, quarantining at home, and monitoring hospital workers. The local government enforced limits on dialysis clinics, which may have influenced patients' fear of death. It also highlights how end-stage renal disease patients may be at risk of increased perceptions of death anxiety in the period COVID-19 as well as sleep disorders and psychological distress.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Iqra Mushtaque b https://orcid.org/0000-0001-7213-6685 Muhammad Awais-E-Yazdan b https://orcid.org/0000-0001-5470-3631

References

Abdul Gafor, A. H., Mohd, R., Cader, R., Kong, W. Y., Mohamad, M., Shah, S. A., Bain, A., & Kong, N. C. (2018). Evaluating cardiovascular risk in chronic kidney disease patients: A biomarker approach. *Sains Malaysiana*, 47(1), 149–155. https://doi.org/10.17576/jsm-2018-4701-18

- Ahmad, W., & Javed, M. (2021). PKRDS data. Pakistan Journal of Kidney Diseases, 5(02), 39. https://doi.org/10.53778/pjkd502168
- Benjamin, O., & Lappin, S. L. (2021). End-stage renal disease. StatPearls [Internet].
- Chan, R. (2012). The effect of acceptance on health outcomes in patients with chronic kidney disease. *Nephrology Dialysis Transplantation*, 28(1), 11–14. https://doi.org/10.1093/ndt/gfs334
- Chapter: 1 Definition and classification of CKD. (2013). Chapter: 1 Definition and classification of CKD. *Kidney International Supplements*, 3(1), 19–62. https://doi.org/10.1038/kisup. 2012.64
- Cheng, Y., Luo, R., Wang, K., Zhang, M., Wang, Z., Dong, L., Li, J., Yao, Y., Ge, S., & Xu, G. (2020). Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney International*, 97(5): 829–838. https://doi.org/10.1016/j.kint.2020.03.005
- Chisini, L. A., Costa, F., dos, S., Demarco, G. T., Silveira, E. R., & Demarco, F. F. (2020). COVID-19 pandemic impact on paediatric dentistry treatments in the Brazilian Public Health System. *International Journal of Paediatric Dentistry*, 31(1), 31–34. https://doi.org/ 10.1111/ipd.12741
- Cohen, S. D., Cukor, D., & Kimmel, P. L. (2016). Anxiety in patients treated with hemodialysis. *Clinical Journal of the American Society of Nephrology*, 11(12), 2250–2255. https://doi.org/ 10.2215/cjn.02590316
- Coppolino, G., Presta, P., Nicotera, R., Placida, G., Vita, C., Carullo, N., Andreucci, M., Bolignano, D., Castagna, A., & Ruotolo, G. (2020). COVID-19 and renal disease in elderly patients. *Geriatric Care*, 6(2). https://doi.org/10.4081/gc.2020.9029
- Coronavirus disease (COVID-19) World Health Organization. (2019). www.who.int. https:// www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid = EAIaIQobChMIvOzpYn78gIViJftCh0vbgDrEAAYASAAEgKX9 D BwE
- Dąbrowska-Bender, M., Dykowska, G., Żuk, W., Milewska, M., & Staniszewska, A. (2018). The impact on quality of life of dialysis patients with renal insufficiency. *Patient Preference and Adherence*, 12, 577–583. https://doi.org/10.2147/ppa.s156356
- Dewina, A., Emaliyawati, E., & Praptiwi, A. (2018). Death Anxiety Level among Patients with Chronic Renal Failure Undergoing Hemodialysis. *Journal of Nursing Care*, 1(1), 1. https:// doi.org/10.24198/jnc.v1i1.15757
- Diao, B., Wang, C., Wang, R., Feng, Z., Tan, Y., Wang, H., Wang, C., Liu, L., Liu, Y., Liu, Y., Wang, G., Yuan, Z., Ren, L., Wu, Y., & Chen, Y. (2020). Human kidney is a target for novel severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection. MedRxiv. https://doi.org/10.1101/2020.03.04.20031120
- Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., Merson, L., Lee, J., Plotkin, D., Sigfrid, L., Halpin, S., Jackson, C., Gamble, C., Horby, P. W., Nguyen-Van-Tam, J. S., & Ho, A. (2020). Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. *BMJ*, 369. https://doi.org/ 10.1136/bmj.m1985
- Eckardt, K.-U., Berns, J. S., Rocco, M. V., & Kasiske, B. L. (2009). Definition and classification of CKD: The debate should be about patient prognosis—A position statement from KDOQI

and KDIGO. American Journal of Kidney Diseases, 53(6), 915–920. https://doi.org/10. 1053/j.ajkd.2009.04.001

- Felton, B. J., & Revenson, T. A. (1984). Coping with chronic illness: A study of illness controllability and the influence of coping strategies on psychological adjustment. *Journal of Consulting and Clinical Psychology*, 52(3), 343–353. https://doi.org/10.1037/0022-006x. 52.3.343
- Fernandes, V. (2012). (Re) discovering the PLS approach in management science. M@ n@ gement, 15(1).
- Fornell, C., & Larcker, D. F. (1981). Structural equation models with unobservable variables and measurement error: Algebra and statistics. *Journal of Marketing Research*, 18(3), 382. https://doi.org/10.2307/3150980
- Gansevoort, R. T., & Hilbrands, L. B. (2020). CKD is a key risk factor for COVID-19 mortality. *Nature Reviews Nephrology*. Advance online publication. https://doi.org/10.1038/s41581-020-00349-4
- García-Llana, H., Remor, E., del Peso, G., Celadilla, O., & Selgas, R. (2013). Motivational interviewing promotes adherence and improves wellbeing in pre-dialysis patients with advanced chronic kidney disease. *Journal of Clinical Psychology in Medical Settings*, 21(1), 103–115. https://doi.org/10.1007/s10880-013-9383-y
- Ghiasi, Z., Alidadi, A., Payandeh, A., Emami, A., & Lotfinia, S. (2021). Health-related quality of life and death anxiety among hemodialysis patients. *Zahedan Journal of Research in Medical Sciences*, 23(2). https://doi.org/10.5812/zjrms.98400
- Goh, Z. S., & Griva, K. (2018). Anxiety and depression in patients with end-stage renal disease: impact and management challenges – a narrative review. *International Journal of Ne*phrology and Renovascular Disease, 11, 93–102. https://doi.org/10.2147/ijnrd.s126615
- Grégoire, Y., & Fisher, R. J. (2006). The effects of relationship quality on customer retaliation. Marketing Letters, 17(1), 31–46. https://doi.org/10.1007/s11002-006-3796-4
- Hair, J., Hult, G. T., Ringle, C., & Sarstedt, M. (2014). A primer on partial least squares structural equation modeling (PLS-SEM). 2014 Faculty Bookshelf.
- Hair, J. F., Hult, G. T. M., Ringle, C. M., & Sarstedt, M. (2017). A primer on partial least squares structural equation modeling (PLS-SEM) (2nd ed.). Sage.
- Hair, J. F. Jr, Hult, G. T. M., Ringle, C., & Sarstedt, M. (2016). *A primer on partial least squares* structural equation modeling (*PLS-SEM*). Sage publications.
- Henseler, J., Hubona, G., & Ray, P. A. (2016). Using PLS path modeling in new technology research: updated guidelines. *Industrial Management & Data Systems*, 116(1), 2–20. https:// www.emerald.com/insight/content/doi/10.1108/IMDS-09-2015-0382/full/html.
- Henseler, J., Ringle, C. M., & Sarstedt, M. (2015). A new criterion for assessing discriminant validity in variance-based structural equation modeling. *Journal of the Academy of Marketing Science*, 43(1), 115–135. https://link.springer.com/article/10.1007/s11747-014-0403-8.
- Hulland, J. (1999). Use of partial least squares (PLS) in strategic management research: A review of four recent studies. *Strategic Management Journal*, 20(2), 195–204. https://doi.org/10. 1002/(SICI)1097-0266(199902)20:2<195::AID-SMJ13>3.0.CO;2-7

- Jankowska-Polańska, B., Uchmanowicz, I., Wysocka, A., Uchmanowicz, B., Lomper, K., & Fal, A. M. (2016). Factors affecting the quality of life of chronic dialysis patients. *The European Journal of Public Health*, 27(2), 262–267. https://doi.org/10.1093/eurpub/ckw193
- Kokoszka, A., Leszczyńska, K., Radzio, R., Daniewska, D., Łukasiewicz, A., Orzechowski, W., Piskorz, A., & Gellert, R. (2016). Prevalence of depressive and anxiety disorders in dialysis patients with chronic kidney disease. *Archives of Psychiatry and Psychotherapy*, 18(1), 8–13. https://doi.org/10.12740/app/61977
- Lee, J., Steel, J., Roumelioti, M.-E., Erickson, S., Myaskovsky, L., Yabes, J. G., Rollman, B. L., Weisbord, S., Unruh, M., & Jhamb, M. (2020). Psychosocial impact of COVID-19 pandemic on patients with end-stage kidney disease on hemodialysis. *Kidney360*, 1(12), 1390–1397. https://doi.org/10.34067/kid.0004662020
- Moorthi, R. N., & Latham-Mintus, K. (2019). Social isolation in chronic kidney disease and the role of mobility limitation. *Clinical Kidney Journal*, 12(4), 602–610. https://doi.org/10. 1093/ckj/sfy134
- Moraes, R. R., Correa, M. B., Queiroz, A. B., Daneris, Â., Lopes, J. P., Pereira-Cenci, T., D'Avila, O. P., Cenci, M. S., Lima, G. S., & Demarco, F. F. (2020). COVID-19 challenges to dentistry in the new pandemic epicenter: Brazil. *Plos One*, 15(11), e0242251. https://doi.org/10.1371/ journal.pone.0242251
- Mushtaque, I., Rizwan, M., Dasti, R. K., Ahmad, R., & Mushtaq, M. (2021b). Students' attitude and impact of online learning; role of teachers and classmate support during the Covid-19 crisis. *Performance Improvement*. Advance online publication. https://doi.org/10.1002/pfi. 21982
- Nataatmadja, M., Evangelidis, N., Manera, K. E., Cho, Y., Johnson, D. W., Craig, J. C., Baumgart, A., Hanson, C. S., Shen, J., Guha, C., Scholes-Robertson, N., & Tong, A. (2020). Perspectives on mental health among patients receiving dialysis. *Nephrology Dialysis Transplantation*, 36(7), 1317–1325. https://doi.org/10.1093/ndt/gfaa346
- Ng, J. H., Hirsch, J. S., Wanchoo, R., Sachdeva, M., Sakhiya, V., Hong, S., Jhaveri, K. D., Fishbane, S., Abate, M., Andrade, H. P., Barnett, R. L., Bellucci, A., Bhaskaran, M. C., Corona, A. G., Flores Chang, B. S., Finger, M., Fishbane, S., Gitman, M., Halinski, C., & Hasan, S. (2020). Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. *Kidney International*, *98*(6), 1530–1539. https://doi.org/10.1016/j.kint.2020. 07.030
- Pfefferbaum, B., & North, C. S. (2020). Mental health and the Covid-19 pandemic. New England Journal of Medicine, 383(6). https://doi.org/10.1056/nejmp2008017
- Pretto, C. R., Winkelmann, E. R., Hildebrandt, L. M., Barbosa, D. A., Colet, C. de F., Stumm, E. M. F., Pretto, C. R., Winkelmann, E. R., Hildebrandt, L. M., Barbosa, D. A., Colet, C. de F., & Stumm, E. M. F. (2020). Calidad de vida de pacientes renales crónicos en hemodiálisis y factores relacionados. *Revista Latino-Americana de Enfermagem*, 28, e3327. https://doi.org/10.1590/1518-8345.3641.3327
- Rajan, E. J. E., & Subramanian, S. (2016). The effect of depression and anxiety on the performance status of end-stage renal disease patients undergoing hemodialysis. *Saudi Journal* of Kidney Diseases and Transplantation, 27(2), 331. https://doi.org/10.4103/1319-2442. 178555

- Saleem, T., Gul, S., & Saleem, S. (2015). Death anxiety scale. *The Professional Medical Journal*, 22(06), 723–732. https://doi.org/10.29309/tpmj/2015.22.06.1239
- Saqib Lodhi, F., Raza, O., Montazeri, A., Nedjat, S., Yaseri, M., & Holakouie-Naieni, K. (2017). Psychometric properties of the Urdu version of the World Health Organization's quality of life questionnaire (WHOQOL-BREF). *Medical Journal of the Islamic Republic of Iran*, 31(1), 853–859. https://doi.org/10.14196/mjiri.31.129
- Song, M.-K., Ward, S., Paul, S., Gilet, C., & Hladik, J. (2017). MP715Trajectories of multidimensional quality of life among patients receiving chronic dialysis. *Nephrology Dialysis Transplantation*, 32(suppl_3), iii696. https://doi.org/10.1093/ndt/gfx180.mp715
- zahra, R., Baig, K., & Sadiq, U. (2020). Illness acceptance diabetes specific distress and quality of life among adolescents with type 1 diabetes mellites. *Pakistan Journal of Physiology*, 16(1), 37–40. http://www.pjp.pps.org.pk/index.php/PJP/article/view/1167.
- Zhang, W. R., & Parikh, C. R. (2019). Biomarkers of Acute and Chronic Kidney Disease. Annual Review of Physiology, 81(1), 309–333. https://doi.org/10.1146/annurev-physiol-020518-114605
- Zyoud, S. H., Daraghmeh, D. N., Mezyed, D. O., Khdeir, R. L., Sawafta, M. N., Ayaseh, N. A., Tabeeb, G. H., Sweileh, W. M., Awang, R., & Al-Jabi, S. W. (2016). Factors affecting quality of life in patients on haemodialysis: A cross-sectional study from Palestine. *BMC Nephrology*, 17(1), 44. https://doi.org/10.1186/s12882-016-0257-z